132 related articles for article (PubMed ID: 24950984)
1. Trebananib: an alternative anti-angiogenic strategy.
Gourley C
Lancet Oncol; 2014 Jul; 15(8):776-7. PubMed ID: 24950984
[No Abstract] [Full Text] [Related]
2. Ovarian cancer: TRINOVA-1, beyond VEGF inhibition.
Villanueva MT
Nat Rev Clin Oncol; 2014 Aug; 11(8):442. PubMed ID: 25001464
[No Abstract] [Full Text] [Related]
3. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Monk BJ; Poveda A; Vergote I; Raspagliesi F; Fujiwara K; Bae DS; Oaknin A; Ray-Coquard I; Provencher DM; Karlan BY; Lhommé C; Richardson G; Rincón DG; Coleman RL; Herzog TJ; Marth C; Brize A; Fabbro M; Redondo A; Bamias A; Tassoudji M; Navale L; Warner DJ; Oza AM
Lancet Oncol; 2014 Jul; 15(8):799-808. PubMed ID: 24950985
[TBL] [Abstract][Full Text] [Related]
4. Incidence and management of edema associated with trebananib (AMG 386).
Monk BJ; Minion L; Lambrechts S; Vergote IB; Devoogdt N; Karlan BY
Gynecol Oncol; 2013 Sep; 130(3):636-41. PubMed ID: 23707665
[No Abstract] [Full Text] [Related]
5. Combining targeted therapies in ovarian cancer.
Scambia G; Salutari V; Ferrandina G
Lancet Oncol; 2014 Oct; 15(11):1179-81. PubMed ID: 25218905
[No Abstract] [Full Text] [Related]
6. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
7. Role of chemotherapy in epithelial ovarian cancer.
Markman M
Minerva Ginecol; 2011 Jun; 63(3):287-97. PubMed ID: 21654613
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
Han ES; Wakabayashi M; Leong L
Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
[TBL] [Abstract][Full Text] [Related]
10. [Effect of evidence-based medicine on the decision of chemotherapy for epithelial ovarian cancer].
Li GT
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):582-6. PubMed ID: 23141177
[No Abstract] [Full Text] [Related]
11. ICON-6: the danger of changing study design midstream.
Norrie J
Lancet; 2016 Mar; 387(10023):1031-1032. PubMed ID: 27025174
[No Abstract] [Full Text] [Related]
12. Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research.
Gadducci A; Lanfredini N; Sergiampietri C
Crit Rev Oncol Hematol; 2015 Oct; 96(1):113-28. PubMed ID: 26126494
[TBL] [Abstract][Full Text] [Related]
13. Recurrent epithelial ovarian cancer: an update on treatment.
Foley OW; Rauh-Hain JA; del Carmen MG
Oncology (Williston Park); 2013 Apr; 27(4):288-94, 298. PubMed ID: 23781692
[TBL] [Abstract][Full Text] [Related]
14. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
[TBL] [Abstract][Full Text] [Related]
15. Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?
McCann GA; Smith B; Backes FJ; Rath K; Chacko S; Salani R; Eisenhauer E; Fowler JM; Cohn DE; O'Malley DM
Gynecol Oncol; 2012 Nov; 127(2):362-6. PubMed ID: 22885866
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1).
Fujiwara K; Monk BJ; Lhommé C; Coleman RL; Brize A; Oaknin A; Ray-Coquard I; Fabbro M; Provencher D; Bamias A; Vergote I; DeCensi A; Zhang K; Vogl FD; Bach BA; Raspagliesi F
Ann Oncol; 2016 Jun; 27(6):1006-1013. PubMed ID: 27029706
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.
Burger RA
Ann Oncol; 2011 Dec; 22 Suppl 8():viii65-viii68. PubMed ID: 22180405
[TBL] [Abstract][Full Text] [Related]
18. A ten-year remission maintained by 6,272 mg (3,920 mg/m2) cumulative dose of cisplatin-based chemotherapy for recurrent epithelial ovarian cancer.
Piver MS
Eur J Gynaecol Oncol; 2001; 22(6):403-5. PubMed ID: 11874068
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in ovarian cancer.
Mountzios G; Pentheroudakis G
N Engl J Med; 2012 Mar; 366(13):1257; author reply 1258. PubMed ID: 22455430
[No Abstract] [Full Text] [Related]
20. Bevacizumab in ovarian cancer.
Copur MS; Obermiller AM; Ramaekers R
N Engl J Med; 2012 Mar; 366(13):1256-7; author reply 1257-8. PubMed ID: 22455429
[No Abstract] [Full Text] [Related]
[Next] [New Search]
